Elicio Therapeutics (ELTX) Capital Expenditures (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Capital Expenditures for 7 consecutive years, with -$170000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures changed N/A year-over-year to -$170000.0; the trailing twelve-month figure through Jun 2026 stood at $225000.0 (up 121.8% YoY), and the FY2025 full-year result was $170000.0, up 107.61% from the prior year.
• Capital Expenditures eased to -$170000.0 in Q2 2026 per ELTX's latest filing, from $225000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $587000.0 in Q2 2022 and bottomed at -$1.0 million in Q2 2024.
• Historically, Capital Expenditures has averaged -$107333.3 across 5 years, with a median of $8500.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures soared 163.89% in 2022, then slumped 2393.33% in 2024.
• Over 5 years, Capital Expenditures stood at $95000.0 in 2022, then sank by 52.63% to $45000.0 in 2023, then plunged by 2393.33% to -$1.0 million in 2024, then soared by 116.47% to $170000.0 in 2025, then plunged by 200.0% to -$170000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$170000.0, $225000.0, and $170000.0 for Q2 2026, Q1 2026, and Q3 2025 respectively.